Lunit Inc. and Summit Therapeutics announced a research agreement to evaluate Lunit’s AI‑powered pathology platform, SCOPE IO, on hematoxylin‑eosin whole‑slide images. The work will focus on extracting quantitative tumor microenvironment features to support biomarker discovery and patient selection for Summit’s bispecific antibody ivodescimab. Both firms say the analysis could provide scalable insights from routine tissue samples without extra stains. The collaboration is for research use only and does not involve clinical outcomes.
Why it matters
If successful, the AI analysis could help drug developers pinpoint which patients are most likely to benefit from ivonescimab.
